Raptor Pharmaceutical Acquires Global Rights to Quinsair For Treating Psuedomonas Aeruginosa in CF

Raptor Pharmaceutical Corp., recently announced it has reached an agreement with Tripex Pharmaceuticals over the rights to Quinsair, a first-of-its-kind inhaled fluoroquinolone indicated for chronic respiratory infections caused by Psuedomonas aeruginosa in adult cystic fibrosis patients. Quinsair was granted marketing authorization by the European Commission and Health Canada earlier this year.

Different Pseudomonas Varieties Found in CF Patient Lungs

Newly found workings of Pseudomonas aeruginosa may explain why certain medications are only modestly effective in patients with cystic fibrosis. A group of researchers led by Dr. Pradeep Singh and Dr. Peter Jorth at the University of Washington School of Medicine discovered that when P. aeruginosa infects cystic fibrosis patients’…